VANCOUVER, Jan. 14, 2013 /PRNewswire/ - Abattis Bioceuticals Corp. (the
"Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces the
engagement of Andrew Riseman Ph.D. effective January 11, 2013. Dr.
Riseman will be assisting the Company in Applied Biology and Plant
Mr. Mike Withrow, Chief Executive Officer on behalf of the Company,
stated, "We are pleased to have Dr. Riseman join our Abattis team. His
expertise in tissue and plant breeding sciences will be a tremendous
asset to Abattis; we will apply his knowledge to produce proprietary
intellectual property for the company. "
Andrew Riseman Ph.D., Associate Professor, Plant Biology and Plant
Breeding at UBC stated, I am very excited about this opportunity to
work with such a great company to advance botanical sciences in the
Medical Marijuana and other medicinal plant breeding sciences, I see
Abattis a company with the ability to engineer, grow and extract
advanced Pharmaceutical Grade Compounds "PGC's" that ensure
traceability, consistency in dosing and safety with a target to produce
the purest compounds from chosen cultivars."
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company with
capabilities through its wholly owned subsidiaries of producing,
licensing and marketing proprietary ingredients and bio-similar
compounds for use in Pharmaceuticals, Nutraceutical, Cosmetic and
Animal Nutrition markets. The company also has a deep pipeline of
proprietary products ready for sale in high growth areas of Functional
Foods and Supplements business. For more information, visit the
Company's website at www.abattis.com.
About Dr. Riseman
ON BEHALF OF THE BOARD
Michael Withrow, President & CEO
Neither the CNSX Exchange nor its regulations services accepts
for the adequacy or accuracy of this release.
SOURCE Abattis Bioceuticals Corp.